Dyne Plans Post-Prasad FDA Run as Duchenne Exon Skipper Sustains Benefit in Long Term Data

Dyne did not reveal specific data from the Phase 1/2 DELIVER study in its Monday news release, pointing instead to an upcoming presentation on …